Drug intelligence / Profile preview

ondansetron + atropine + bupivacaine

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Intrathecal

Overview

A combination of medications used in anesthesia practice, particularly during spinal anesthesia. Ondansetron is a serotonin 5-HT3 receptor antagonist that helps prevent nausea, vomiting, and hypotension. Atropine is an anticholinergic agent that prevents bradycardia by blocking cholinergic receptors. Bupivacaine is a local anesthetic used for regional anesthesia. When used together, these medications have complementary effects in preventing and treating complications associated with spinal anesthesia, including hypotension, bradycardia, and asystole.

Targets

NaV alpha (Voltage-gated sodium channel alpha subunit family)HTR3A (5-hydroxytryptamine receptor 3A)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on ondansetron + atropine + bupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ondansetron + atropine + bupivacaine.

Explore the full profile